Search

Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter – Anaphylaxis and Other Serious Hypersensitivity Reactions

Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of Varubi (rolapitant) injectable emulsion. Most reactions have occurred within the first few minutes of administration. Symptoms of anaphylaxis can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping, abdominal pain or vomiting; back pain or chest pain; hypotension or shock.

[button link=”https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm592592.htm” color=”default”]Full Alert[/button]

[spacer height=”20px”]

[ctt link=”7tQfJ” template=”1″]ReTweet if useful… Anaphylaxis and other serious hypersensitivity reactions to rolapitant injectable emulsion https://ctt.ec/7tQfJ+ @ivteam #ivteam[/ctt]

Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]